Ustekinumab/Ustekinumab

Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period. Keywords: Anti-IL-12/23, p40, ustekinumab Ustekinumab interlokin-12 (IL-12) ve IL-23'un ortak alt birimi p40'i hedef alan immunoglobulin G1 yapisinda bir monoklonal antikordur. Klinik arajtirmalarda PAJI75 yaniti saglanan hasta oranlari %66 ile 81 arasinda degijmektedir. Gercek yajam calijmalarinda ise uzun ilac sagkalim suresi ile one cikmaktadir. Vucut agirligina gore doz secimi yapildigi icin obez hastalarda kullanim kolayligi ve idame doneminde 12 haftada bir uygulanmasi ustekinumabin diger avantajlaridir. Anahtar Kelimeler: Anti-IL-12/23, p40, ustekinumab